- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00199186
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
October 18, 2007 updated by: Johann Wolfgang Goethe University Hospital
A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia (ALL)
The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with Philadelphia positive (Ph+)ALL, whether this treatment is better tolerated, and whether subsequent combination therapy with imatinib and chemotherapy of approximately a 1 year duration is tolerable and effective with respect to maintaining remissions.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Oliver G Ottmann, M.D.
- Phone Number: 6221 ++49-69-6301-0
- Email: ottmann@em.uni-frankfurt.de
Study Contact Backup
- Name: Barbara Wassmann, M.D.
- Phone Number: 6221 ++49-69-6301-0
- Email: wassmann@em.uni-frankfurt.de
Study Locations
-
-
-
Frankfurt/Main, Germany, 60590
- Recruiting
- Medizinische Klinik II, Johann Wolfgang Goethe Universität
-
Contact:
- Oliver G Ottmann, M.D.
- Phone Number: 6221 ++49-69-6301-0
- Email: ottmann@em.uni-frankfurt.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
56 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients
- Age > 55 years (biological age)
- Diagnosis of Ph1 chromosome-positive ALL (pre-B, common- or pre-pre-B ALL)
- Newly diagnosed, lymphoid blast crisis of chronic myeloid leukemia
- Only pre-phase chemotherapy prior to study start
- World Health Organization (WHO) status 0, 1 or 2
- Voluntary written informed consent
Exclusion Criteria:
- Creatinine levels more than 2 x the upper limit of normal (ULN)
- Total serum bilirubin more than 1.5 x the ULN
- AST (SGOT) or ALT (SGPT) more than 5 x the ULN
- Any other prior antineoplastic treatment except for pre-phase chemotherapy
- Active central nervous system (CNS) leukemia
- New York Heart Association (NYHA) grade 3/4 cardiac disease
- Active severe infection
- Serious concomitant medical condition
- Patients with a history of non-compliance to medical regimens
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Remission rate after induction therapy
|
Secondary Outcome Measures
Outcome Measure |
---|
Overall survival
|
Disease free survival
|
Remission duration
|
Mortality rate during induction
|
Severe adverse events during induction
|
Efficacy of salvage therapy after crossover
|
Levels of minimal residual disease
|
Incidence of relapse
|
Frequency of point mutations in the BCR-ABL gene
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Oliver G Ottmann, M.D., Medizinische Klinik II, Johann Wolfgang Goethe Universität
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2002
Study Registration Dates
First Submitted
September 16, 2005
First Submitted That Met QC Criteria
September 16, 2005
First Posted (Estimate)
September 20, 2005
Study Record Updates
Last Update Posted (Estimate)
October 19, 2007
Last Update Submitted That Met QC Criteria
October 18, 2007
Last Verified
September 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplastic Processes
- Cell Transformation, Neoplastic
- Carcinogenesis
- Leukemia, Myeloid
- Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Blast Crisis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Cyclophosphamide
- Cytarabine
- Methotrexate
- Vincristine
- Idarubicin
- Imatinib Mesylate
Other Study ID Numbers
- CSTI571ADE10
- GMALL-STI571-ELDERLY-01/02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Philadelphia Positive Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingALL, Adult | Philadelphia-Positive ALL | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)Italy
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingPhiladelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD19 PositiveUnited States
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveSpain
-
Crystal Mackall, MDRecruitingRecurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 PositiveUnited States
-
Bristol-Myers SquibbCompletedChronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positiveNetherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases Hospital...RecruitingPhiladelphia Chromosome Positive Acute Lymphoblastic LeukemiaChina
-
Goethe UniversityCompletedPhiladelphia Positive Acute Lymphoblastic LeukemiaGermany
-
Goethe UniversityGerman Federal Ministry of Education and Research; Deutsche Leukämie- & Lymphom-HilfeRecruitingPhiladelphia Chromosome Positive Acute Lymphoblastic LeukemiaGermany
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted